siRNA and cancer immunotherapy

Immunotherapeutic approaches have been gaining attention in the field of cancer treatment because of their possible ability to eradicate cancer cells as well as metastases by recruiting the host immune system. On the other hand, RNA-based therapeutics with the ability to silence expression of specif...

Full description

Saved in:
Bibliographic Details
Published inImmunotherapy Vol. 4; no. 9; pp. 907 - 917
Main Authors Ghafouri-Fard, Soudeh, Ghafouri-Fard, Somayyeh
Format Journal Article
LanguageEnglish
Published England Future Medicine Ltd 01.09.2012
Subjects
Animal models
Animals
Cancer
cancer immunotherapy
Care and treatment
Clinical trials
Clinical Trials as Topic
Cytokines - antagonists & inhibitors
Cytokines - genetics
Dendritic Cells - immunology
Gene Silencing
Genetic aspects
Health aspects
Humans
immune evasion
Immune response
immune surveillance
Immune system
Immunotherapy
Immunotherapy - methods
Medical research
Metastases
Neoplasms - immunology
Neoplasms - therapy
Physiological aspects
Proteins
RNA
RNA Interference
RNA, Small Interfering - genetics
RNA-mediated interference
RNAi
siRNA
Studies
T cells
T-Lymphocytes - immunology
Toll-Like Receptors - physiology
Tumor cell lines
Tumor cells
Tumors
Iran
Online AccessGet full text

Cover

More Information
Summary:Immunotherapeutic approaches have been gaining attention in the field of cancer treatment because of their possible ability to eradicate cancer cells as well as metastases by recruiting the host immune system. On the other hand, RNA-based therapeutics with the ability to silence expression of specific targets are currently under clinical investigation for various disorders including cancer. As the mechanisms of tumor evasion from the host immune system are versatile, different molecules have the capacity to be targeted by RNAi technology in order to enhance the immune response against tumors. This technology has been used to silence specific targets in tumor cells, as well as immune cells in cancer cell lines, animal models and clinical trials. siRNAs can also stimulate innate immune responses through activation of Tolllike receptors. Although currently clinical trials of the application of siRNA in cancer immunotherapy are few, it is predicted that in future this technology will be used broadly in cancer treatment.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ISSN:1750-743X
1750-7448
DOI:10.2217/imt.12.87